ReviewCurrent hematologic malignancy reports2011
Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?
Review in Current hematologic malignancy reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- Trial
- Small biopsy diagnosis of anterior mediastinal masses: histologic, immunohistochemical, and molecular considerations.Mediastinum (Hong Kong, China) · 2026Review
- Thinking Outside the Box in Mediastinal Lymphoma Management.Clinical hematology international · 2023Article
- Diagnostic approach to prevascular (anterior) mediastinal lymphomas: when thoracic pathology meets hematopathology.Mediastinum (Hong Kong, China) · 2023Review
- Review
- Ruxolitinib significantly enhancesOncotarget · 2018Article
- Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.Blood advances · 2017Article
- Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies.Hematology. American Society of Hematology. Education Program · 2017Review
- Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.The Journal of pathology · 2017Article
- Primary splenic B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A case report.Oncology letters · 2016Article
- Histopathological difficulties in an adolescent lymphoma patient.Pathology oncology research : POR · 2015Article
- Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.The American journal of surgical pathology · 2014Article
- Primary mediastinal large B-cell lymphoma.Current hematologic malignancy reports · 2014Article
- Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Nature reviews. Clinical oncology · 2014Review
- B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma.Medical molecular morphology · 2013Article
- CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.The American journal of pathology · 2012Article
- Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?Current hematologic malignancy reports · 2012Review
- The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.Cancer journal (Sudbury, Mass.)Review
- Primary mediastinal lymphomas, their morphological features and comparative evaluation.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
In recent years, an overlap in biologic and clinical features has been identified between classic Hodgkin lymphoma (CHL) and primary mediastinal large B-cell lymphoma (PMBL). Further strengthening this relationship is the identification of lymphomas with clinical and morphologic features transitional between the two, known as gray zone lymphomas (GZL). However, this diagnostic gray zone is not just of theoretical interest: it presents a practical problem, as the treatment approaches for CHL traditionally differ from those for aggressive B-cell lymphomas. This article reviews the treatment approach for mediastinal lymphomas, including CHL of the nodular sclerosis subtype (CHL-NS), PMBL, and mediastinal GZL. Though several trials have evaluated different regimens with or without radiation in PMBL and CHL-NS, there is a lack of prospective experience in treating GZL because of the rarity of these tumors. Historical data indicate that they have done poorly with traditional approaches developed for the treatment of either CHL or diffuse large B-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.